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Abstract   
Objective 
Grip strength and diabetes are predictors of mortality and cardiovascular disease (CVD), but it is not known 
whether these risk factors interact in predisposing to adverse health outcomes. The aim of the current study was 
to determine the interactions between diabetes and grip strength and their association with health outcomes. 
Research Design and Methods 
We undertook a prospective, general population cohort study using UK Biobank. Cox proportional hazard models 
were used to explore the associations between both grip strength and diabetes and the outcomes of all-cause 
mortality and CVD incidence/mortality, and to test for interactions between diabetes and grip strength.  
Results 
Of 347,130 UK Biobank participants with full data available (mean age 55.9 years, BMI 27.2 kg.m-2, 54.2% were 
women), 13,373 (4.0%) people who reported having diabetes were included in the analysis. Over a median follow-
up of 4.9 years [range: 3.3-7.8], 6,209 died; (594 from CVD) and 4,301 participants developed CVD. People with 
diabetes were at higher risk of all-cause and CVD mortality and CVD incidence. There were significant 
interactions (p<0.05) whereby the risk of CVD mortality was higher in participants with diabetes with low (HR: 
4.05 [2.72; 5.80]) compared to high grip strength (HR: 1.46 [0.87; 2.46]). Similar results were observed for all-
cause mortality and CVD incidence.  
Conclusions 
Risk of adverse health outcomes among people with diabetes is lower in those with high grip strength. Low grip 
strength may be useful to identify a higher risk sub-group of diabetes patients. Intervention studies are required 
to determine if resistance exercise can reduce risk.   
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Introduction 
Low muscle function, measured by grip strength, is associated with an increased risk of all-cause mortality, 
cardiovascular mortality and cardiovascular disease (CVD) (1). Even during healthy ageing, muscle function and 
mass decrease from around 40-45 years of age, with the mechanisms underlying this observation currently 
unknown (2). This loss of muscle mass and function appears to be accelerated in people with type 2 diabetes. 
Indeed, it has been shown in cross-sectional analysis of data from the Health, Ageing and Body Composition 
Study (485 adults 70-79 years of age with type 2 diabetes and 2,133 without) that people with type 2 diabetes 
have lower leg (men only) and grip strength (3) and, after 6 years of follow-up, lose leg, but not grip, strength at 
a greater rate compared to healthy counterparts of comparable age (4,5).  
 
As skeletal muscle function is associated with health outcomes this lower muscle function could potentially 
contribute to the greater risk of developing co-morbidities and mortality in people with type 2 diabetes. In that 
regard, as well as the accelerated loss of muscle mass/function, it has been shown that people with type 2 diabetes 
are at a greater risk of all-cause and CVD mortality (6,7), with this risk higher again the longer a person has type 
2 diabetes (8,9). Prior research has reported that, within a group of people (mean age 63.6 years) with impaired 
fasting glucose/impaired glucose tolerance or type 2 diabetes (n=12,516), a higher grip strength was associated 
with lower all-cause and cardiovascular mortality (10) reflecting the findings observed in general population 
studies. This analysis was, however, only adjusted for BMI, waist circumference, and hip circumference and not 
wider lifestyle factors and had no comparison of this relationship to people without diabetes. Whether this 
relationship holds after more robust adjustment and how these risks compare to people without type 2 diabetes 
remains to be established. 
 
The aim of the current study was to explore the associations of diabetes and grip strength with risk of all-cause 
mortality/CVD incidence in UK Biobank, a large population cohort study of participants aged 40-69 years.  
 
Methods 
Study design 
Between April 2007 and December 2010, UK Biobank recruited 502,628 participants (5.5% response rate), the 
majority of whom were aged 40-70 years, from the general population (11). Participants attended one of 22 
assessment centres across England, Wales and Scotland (12,13) where they completed a touch-screen 
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questionnaire, had physical measurements taken and provided biological samples, as described in detail elsewhere 
(12,13). In this population-based study, all-cause and CVD mortality, and incident CVD events were the main 
outcomes; and diabetes was the exposure of interest. Handgrip strength was treated as a potential effect modifier. 
Socio-demographic factors (age, ethnicity, Townsend deprivation index, professional qualifications, income, 
employment and month of recruitment), health-related variables (duration of years with diabetes, systolic blood 
pressure, medication history for diabetes (insulin), cholesterol and blood pressure as well as prevalent diabetes 
and hypertension at baseline) and lifestyle factors including smoking status, body mass index categories, time 
spent on TV-viewing, discretionary PC-screen time, total physical activity, sleep duration categories and dietary 
intake (processed meat, red meat, oily fish, fruit and vegetables and alcohol intake) were treated as potential 
confounders. Presence of diabetes was determined from self-report of a physician diagnosis. This will capture 
both people with type 1 and type 2 diabetes and in our analysis we have excluded those who developed diabetes 
under the age of 30 (n=1,663) and so will capture, primarily, people with type 2 diabetes. We also excluded 
participants who did not answer this question (n=1,747) and who had prior gestational diabetes (n=1,072), the 
latter due to its often temporary nature. To reduce the effect of reverse causality all-analysis were performed as 
landmark with follow-up commencing two years after recruitment and including participants who were event-free 
at this time. In addition, participants with comorbidities at baseline were excluded from all-analysis (depression, 
COPD, chronic asthma, chronic liver diseases, alcohol problems, substance abuse, eating disorders, schizophrenia, 
cognitive impartment, Parkinson, dementia, chronic pain syndrome, heart diseases, inflammatory diseases, 
arthrosis, arthritis and cancer (n= 103,755). We included 13,373 people with diabetes in the study. 
 
Study procedures 
Date of death was obtained from death certificates held within the National Health Service (NHS) Information 
Centre (England and Wales) and the NHS Central Register Scotland (Scotland). Date and cause of hospital 
admissions were identified via record linkage to Health Episode Statistics (HES) (England and Wales) and to the 
Scottish Morbidity Records (SMR1) (Scotland). Detailed information regarding the linkage procedure can be 
found at http://www.ic.nhs.uk/services/medical-research-information-service. At the time of analysis, mortality 
data were available up to 31st January 2016. Mortality analysis was therefore censored at these dates or date of 
death if this occurred earlier. Hospital admission data were available until 31st March 2015, resulting in disease 
specific outcome analysis being censored at these dates, or the date of first disease incident or death if these 
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occurred earlier. Incident CVD was defined as a hospital admission or death with ICD10 code I60, I61, I63, I64, 
I21, I21.4 and I21.9. 
Grip strength, as a proxy for muscular strength, was measured using a Jamar J00105 hydraulic hand dynamometer. 
Isometric grip force was assessed from a single 3-second maximal grip effort of the right and left arms with the 
participant seated upright with their elbow by their side and flexed at 90º so that their forearm was facing forwards 
and resting on an armrest. The mean of the right and left values, expressed in absolute units (kg), as reported 
elsewhere was used in the current study (14). For the purpose of this study and to take into account biological 
differences in grip strength within sex and age groups we derived age and sex-specific categories of grip strength 
(Table S1).  
Physical activity was based on self-report, using the IPAQ short form (15), and total physical activity was 
computed as the sum of walking, moderate and vigorous activity, measured as metabolic equivalents (MET-
hours/week). Participants were excluded from the analyses if they recorded implausible values; defined as the 
sum of their total physical activity, sleeping time and total screen-time exceeding 24 hours (n=705 participants 
were excluded). Discretionary time spent on TV-viewing and PC-screen were collected using self-reported 
questionnaires. Subjective sleep duration was obtained by asking: "About how many hours sleep do you get in 
every 24 hours?” and then based on this question we derived a categorical sleep duration variable (short sleeper 
<7 h.day-1, normal sleeper 7-9 h.day-1 or long sleepers >9 h.day-1). 
Dietary information was collected in a subset of participants (n=157,223 with dietary and diabetes data available) 
via the Oxford WebQ; a web-based 24h recall questionnaire which was developed specifically as a low-cost 
instrument for assessing diet in large-scale prospective studies. Compared with 24 h dietary recall, the mean 
Spearman's correlation of the 21 nutrients obtained from the WebQ was 0·6, with the majority between 0·5 and 
0·9. The mean differences in intake were less than ±10 % for all nutrients except for carotene and vitamins B12 
and D (16). The Oxford WebQ derives energy intake (total and from specific macronutrients) from the information 
recorded in McCance and Widdowson’s The Composition of Food, 5th edition (17). For participants who 
completed more than one online dietary questionnaire, mean values were calculated from all of the information 
provided, with variation between repeated measurement ranging from 26-34%, as described elsewhere (16). The 
intake of other food items such as red meat, processed meat, oily fish and fruit and vegetable were collected using 
a touchscreen questionnaire on the reported frequency of intake of these food items. These data were available for 
all participants.   
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Area-based socioeconomic status was derived from postcode of residence, using the Townsend score (18). Other 
socio-demographic information such as employment (paid employment, retired, unable to work, unemployed, 
student and other), professional qualifications (college or university, A or O levels, GCSE, CSEs or equivalent 
levels) and income (<£18,000, £18,000-29,999, £30,000-51,999, £52,000-100,000 and >£100,000) were self-
reported at baseline. Age was calculated from dates of birth and baseline assessment. Smoking status was 
categorised into never, former and current smoker. Medical history (physician diagnosis of depression, COPD, 
chronic asthma, chronic liver diseases, alcohol problems, substance abuse, eating disorders, schizophrenia, 
cognitive impartment, Parkinson, dementia, chronic pain syndrome, heart diseases, inflammatory diseases, 
arthrosis, arthritis and cancer) was collected from the self-completed, baseline assessment questionnaire. Number 
of years with diabetes was derived from self-reported age at the assessment visit and age when diabetes was 
diagnosed. History of recent medication for diabetes (insulin), cholesterol and hypertension at baseline were 
collected by self-reported touch-screen questionnaire. Height and body weight were measured by trained nurses 
during the initial assessment centre visit. Body mass index (BMI) was calculated as (weight/height2) and the WHO 
criteria were used to classify BMI into: underweight <18.5, normal weight 18.5-24.9, overweight 25.0-29.9 and 
obese ≥30.0 kg.m-2. Waist circumference was measured using a standardised protocol by trained nurses and central 
obesity was derived using 88cm and 102cm as cut-off points for women and men respectively. Body composition 
(body fat as percentage and fat free mass in kg) was measured by trained nurses using bio-impedance (Range 1% 
- 75% in 0.1% increments) using the Tanita BC418MA body composition analyser. Further details of these 
measurements can be found in the UK Biobank online protocol (http://www.ukbiobank.ac.uk). 
Statistical analysis 
Associations between diabetes and prospective health outcomes (all-cause mortality, CVD incidence and CVD 
mortality) were investigated using Cox-proportional hazard models. The results were reported as hazard ratios 
together with 95% CI. To reduce the effect of reverse causality all-analysis were performed as a landmark analysis 
with follow-up commencing two years after recruitment and including participants who were event-free at this 
time. In addition, participants with comorbidities at baseline were excluded from all-analysis (n= 103,755).  
 
First, to investigate whether diabetes diagnose was associated with a higher hazard for mortality and CVD 
incidence we performed cox-regression analysis fitting diabetes into our model as a binary variable (No=0; 
Yes=1), all analysis are presented as the 3 models adjusted as specified below.  
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Second, to investigate whether levels of grip strength modified the associations between diabetes and health 
outcomes multiplicative interaction between diabetes and age-sex-specific categories of grip strength (coded as 
ordinal variable i.e. High=0, Middle=1, Low=2) were investigated by fitting the relevant parameters into the 
model. Linearity was explored with fractional polynomials models for each exposure, with no evidence of 
deviation from linearity. For all analyses, we ran three incremental models that included an increasing number of 
covariates: “model 0” included age, sex, ethnicity, deprivation index, professional qualifications, gross income, 
employment and month of recruitment as covariates; “model 1”, was also adjusted for duration of diabetes, 
systolic blood pressure, baseline prevalence of hypertension and history of recent medication for diabetes 
(insulin), hypertension and cholesterol; “model 2” was adjusted for model 1 plus lifestyle factors including BMI 
categories, smoking, TV-viewing, PC-screen time, categories of sleep duration and dietary intake (alcohol, fruit 
and vegetable, red meat, processed meat and oily fish intake). Physical activity was included as covariate only 
when the association between diabetes and health outcomes was investigated but not for the interaction between 
grip strength and diabetes, as grip strength is a proxy of total levels of physical activity across the lifespan.  The 
proportional hazard assumption were checked by tests based on Schoenfeld residuals. All analyses were 
performed using STATA 14 MD statistical software (StataCorp LP). 
 
Results 
Of the 502,628 participants recruited to UK Biobank, 498,348 provided data on diabetes status with 13,373 
(diagnosed after 30 years of age and having no baseline co-morbidities) reporting having diabetes being included 
in this study. The mean follow-up period was 4.9 years [ranging from 3.3-7.8] for all-cause and CVD mortality, 
and 4.0 years [ranging from 2.4 to 7.0] for CVD incidence. Over the follow-up period, 4,301 participants 
developed CVD and there were 6,209 deaths: 594 from CVD.  
 
The main characteristics of the participants by diabetes status and categories of grip strength are summarised in 
Table 1. The hazard ratios for all-cause mortality, and CVD incidence and mortality were significantly higher in 
individuals with diabetes compared to those without diabetes (Table 2). Although the associations were slightly 
attenuated after adjustment for further confounding factors, the associations remained significant. Additionally, 
the association between diabetes and health outcomes was modify by grip strength, with significant interactions 
between diabetes and grip strength for all-cause mortality (model 3 p=0.020), CVD mortality (model 3 p=0.016) 
and CVD incidence (model 3 p=0.041) (Figure 1 and Table 3). Compared to non-diabetic individuals with high 
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grip strength, diabetic individuals with low grip strength had a higher risk of all-cause mortality (HR: 2.79 [2.41; 
3.23], p<0.0001), CVD mortality (HR: 4.05 [2.72; 5.80], p<0.0001) and CVD incidence (HR: 2.19 [1.81; 2.64], 
p<0.0001) in model 3. In contrast, diabetic participants with high grip strength were at higher risk of all-cause 
mortality (HR: 1.36 [1.15; 1.61], p<0.0001) but did not have significantly increased risk of CVD mortality (HR: 
1.46 [0.87; 2.46]) or CVD incidence (HR: 1.11 [0.90; 1.37]) (Figure 1). The trend hazard ratios per category 
decrease in grip strength for participants with and without diabetes, across all 3 models, are also summarised in 
Table 3. Although the association were slightly attenuated these remained significant for all three levels of 
adjustments.   
 
Discussion 
The main finding of the current study is that the higher risk of CVD associated with diabetes was restricted to the 
sub-group of people with diabetes with low grip strength; in contrast people with diabetes and high grip strength 
were not at significantly increased risk of CVD.  
 
As skeletal muscle is of primary importance from not only a functional point of view (19) but also as the primary 
protein store and site of glucose disposal (20–22) it has a clearly important metabolic role (23). Indeed, as 
demonstrated in our previous work, low grip strength is associated with a higher diabetes prevalence (24). The 
findings of the current study that diabetes is associated with a lower grip strength is in agreement with previously 
published literature which has demonstrated that a lower, and a more rapid loss of, muscle strength in people with 
type 2 diabetes (3,5). The precise mechanisms underlying this lower muscle mass in people with diabetes has yet 
to be determined, and prior to the current study there had been no investigation of how muscle function interacts 
with the deleterious effects of diabetes on health outcomes.  
 
It is well established that people with type 2 diabetes are at a greater risk of all-cause mortality and that CVD rates 
are higher (6,7), and that this risk increases the longer a person has type 2 diabetes (8,9). Our data has demonstrated 
that a low grip strength is associated with further elevations in the already high risk of all-cause mortality, CVD 
incidence and mortality in people with diabetes. These findings are in agreement with the findings of Lopez-
Jaramillo et al (10) and confirming that such associations exist in a larger population and remain even after 
adjustment for a wide variety of socio-demographic and lifestyle factors, comorbidities and the duration of 
diagnosed diabetes. We were able to extend this previous work by also comparing these associations with a 
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population without diabetes. Indeed, relative to those without diabetes and with a high grip strength, those with 
low grip strength had higher hazards for all-cause and CVD mortality, and CVD incidence in both people with 
and without diabetes. In those with both diabetes and high grip strength a higher hazard for all-cause mortality, 
relative to those without diabetes and with a high grip strength, was observed with no difference in the hazard for 
CVD mortality and incidence. These data have clear implications for public health policies and indicate that, in 
people with diabetes, targeting interventions at those with low grip strength may have a greater impact. These 
associations remain to be investigated in appropriately designed randomised controlled trials to determine whether 
and to what extent they are causal.  
 
There is some precedence to indicate that these associations may be causal and for such interventions to be 
beneficial. For example, a general lifestyle intervention in people with impaired glucose tolerance has been shown 
to reduce incidence of cardiovascular and all-cause mortality and diabetes (25). These findings are not ubiquitous, 
however, with the look AHEAD trial finding no effect of an intensive lifestyle intervention on cardiovascular 
events in overweight/obese adults with type 2 diabetes (26). Neither of these interventions were, however, 
designed to increase strength specifically. The main way to increase muscle strength is via resistance exercise 
training, which has been shown, in trials, to improve many CVD risk factors (27). If causality was demonstrated, 
the implementation of the measurement of grip strength in a clinical setting would be relatively straightforward 
as its measurement requires little training, is simple and cheap to administer, and has high reproducibility (28). 
Grip strength could even be used to screen patients with diabetes (or even more widely) to target interventions 
where the largest benefits could be gained. It is worth noting that whilst grip strength is highly correlated with leg 
strength, and this provides a valid index of whole-body muscle strength across the age range (29) it is not as 
sensitive, relative to lower leg strength, to the effects of short-term resistance exercise training (30). Therefore, 
whilst monitoring grip strength may be useful in identify at risk populations, it may not be useful in monitoring 
the efficacy of resistance exercise interventions employed.  
 
Strengths and limitations 
Although UK Biobank is not representative of the general population, with evidence of a 'healthy volunteer' 
selection bias, the valid assessment of exposure-disease relationships may be widely generalizable and does not 
require participants to be representative of the population at large (31). Therefore, caution should be heeded in 
generalizing summary statistics, such as the prevalence of diabetes or obesity, to the general population. This does 
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not detract from the ability to generalize estimates of the magnitude of associations. Our study benefited from a 
very large number of participants, recruited from the general population, across the whole of the UK. We had 
sufficient power to undertake analysis by age and grip strength categories. It is possible however that rather than 
grip strength having a causally protective effect vs. mortality or subsequent disease incidence, it may be a marker 
of generally better health at baseline and whilst we have attempted to reduce the potential for reverse causality 
and confounding in our analysis, by performing a 2 years landmark analysis and excluding individuals with 
medical diagnosis of chronic comorbidities at baseline, the potential for both to influence the results does remain. 
A further limitation to the current study is that there is bias in our data as it only includes people with diabetes 
who had survived long enough to be recruited in to the study. Diabetes was ascertained by self-report of a 
physician diagnosis. Therefore, incomplete ascertainment is possible but unlikely to introduce a systematic error. 
Indeed, Bays et al. (33) reported that the prevalence of diabetes was similar when based solely on self-report in 
the SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes) 
screening survey compared with clinical and laboratory corroboration of self-reports in the National Health and 
Nutrition Examination Survey. Schneider et al. (34) also showed that self-reported diabetes was >92% reliable 
and 83% sensitive. We were unable to differentiate between type 1 and type 2 diabetes but with the exclusion of 
participants <30 years the overwhelming majority of cases will be type 2. Data on physical activity and sedentary 
behaviour was self-reported which has limitations in accuracy (35) and does not capture specific forms of exercise, 
such as resistance training, which is likely to have an effect on the associations we have observed in the current 
study. In all studies involving nutritional epidemiology there are always uncertainties in estimating long-term 
dietary intake and all methods of dietary assessment can incur both random and systematic errors; the former of 
which can be diminished, but not eliminated, by studying large numbers (36,37). In this study dietary intake was 
self-reported outside the clinic, which may encourage more truthful reporting. In addition, online administration 
of the questionnaires is expected to minimize any reporting bias due to social desirability. The information was 
collected using a 24-h recall questionnaire which has been shown to produce more accurate results than a food 
frequency questionnaire (the usual approach adopted in large-scale studies) (38). 
 
The current study shown that the risk all-cause and CVD mortality, and CVD incidence is lower in those with a 
higher grip strength, in people both with and without diabetes. Our findings therefore suggest that grip strength 
may have clinical utility in identifying people with diabetes at risk of poorer health outcomes. Furthermore 
targeting interventions, such as resistance exercise, to those with low grip strength, where the greatest benefits 
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may be gained could, increase clinical effectiveness. These conclusions remain to be tested in future well designed 
randomised controlled trials.  
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Figure legend 
Figure 1.  Association of all-cause mortality and CVD incidence and mortality by diabetes and grip strength 
strata. Data presented as hazard ratio and their 95% CI. Individuals with diabetes and high grip strength were used 
as reference group. The model was adjusted for age, sex, ethnicity, deprivation index, professional qualifications, 
gross income, employment and month of recruitment, duration of diabetes, systolic blood pressure, baseline 
prevalence of hypertension and history of recent medication for diabetes (insulin), hypertension and cholesterol, 
BMI categories, smoking, TV-viewing, PC-screen time, categories of sleep duration, physical activity and dietary 
intake (alcohol, fruit and vegetable, red meat, processed meat and oily fish intake). All-cause mortality was 
additionally adjusted for CVD diagnosed at baseline.   
  
17 
 
Table 1. Cohort characteristics by categories of handgrip strength and diabetes diagnosed 
  Without diabetes With diabetes 
Socio-demographics Overall Low strength Middle 
strength 
Higher 
strength 
Low strength Middle 
strength  
Higher 
strength 
Total n 347,130 60,979 136,679 136,099  3,749 5,367  4,257 
Women, n (%) 188,171 (54.2) 33,043 (54.2) 75,350 (55.1) 74,562 (54.8) 1,410 (37.6) 2,030 (37.8) 1,776 (41.7) 
Age (years), mean (SD) 55.9 (8.1) 55.9 (8.0) 56.0 (8.1) 55.4 (8.2) 59.1 (7.2) 59.4 (7.2) 58.8 (7.2) 
Deprivation index quintiles, n (%)        
   Lower 120,852 (34.8) 18,352 (30.1) 47,745 (35.0) 51,088 (37.5) 810 (21.6) 1,501 (28.0) 1,356 (31.9) 
   Middle 118,416 (34.1) 19,981 (32.8) 46,921 (34.3) 47,215 (34.7) 1,112 (29.7) 1,743 (32.5) 1,444 (33.9) 
   Higher 107,862 (31.1) 22,646 (37.1) 42,013 (30.7) 37,796 (27.8) 1,827 (48.7) 2,123 (39.5) 1,457 (34.2) 
Professional qualifications, n (%)        
   College or University degree 118,754 (40.4) 18,999 (38.5) 46,573 (40.3) 49,682 (41.9) 908 (34.1) 1,397 (34.0) 1,195 (35.6) 
   A levels/AS levels or equivalent 39,908 (13.6) 6,714 (13.6) 15,572 (13.5) 16,313 (13.7) 339 (12.7) 567 (13.8) 403 (12.0) 
   O levels/GCSEs or equivalent 75,581 (25.7) 13,054 (26.4) 30,301 (26.2) 29,464 (24.8) 718 (27.0) 1,144 (27.9) 900 (26.8) 
   CSEs or equivalent 20,044 (6.8) 3,926 (7.9) 7,919 (6.9) 7,531 (6.3) 210 (7.8) 251 (6.1) 207 (6.1) 
   NVQ or HND or HNC or equivalent 22,247 (7.6) 3,778 (7.6) 8,543 (7.4) 8,821 (7.4) 268 (10.1) 438 (10.7) 399 (11.9) 
   Other professional qualifications 17,424 (5.9) 2,980 (6.0) 6,691 (5.7) 6,969 (5.9) 221 (8.3) 307 (7.5) 256 (7.6) 
Income categories, n (%)        
   Less than £18,000 57,816 (19.2) 12,637 (24.4) 22,813 (19.2) 18,798 (15.7) 1,268 (40.6) 1,377 (30.3) 923 (25.3) 
   £18,000 to £51,999 157,608 (52.2) 26,720 (51.7) 62,401 (52.5) 62,778 (52.4) 1,434 (45.9) 2,342 (51.6) 1,933 (53.0) 
   Greater than £52,000 86,251 (28.6) 12,378 (23.9) 33,623 (28.3) 38,209 (31.9) 425 (13.5) 824 (18.1) 792 (21.7) 
Employment status, n (%)        
   In paid employment or self-employed 216,635 (62.9) 36,259 (60.1) 85,494 (63.1) 88,582 (65.5) 1,579 (42.8) 2,502 (47.1) 2,219 (52.5) 
   Retired 104,497 (30.4) 18,457 (30.6) 41,648 (30.7) 38,746 (28.7) 1,556 (42.4) 2,385 (44.8) 1,705 (40.4) 
   Looking after home and/or family 9,845 (2.9) 1,728 (2.9) 3,797 (2.8) 4,026 (3.0) 99 (2.6) 106 (2.0) 89 (2.1) 
   Unable to work because of sickness or 
disability 
5,269 (1.5) 2,067 (3.4) 1,537 (1.1) 1,094 (0.8) 296 (8.0) 177 (3.3) 98 (2.3) 
   Unemployed 5,498 (1.6) 1,339 (2.2) 2,140 (1.6) 1,683 (1.3) 132 (3.6) 116 (2.2) 88 (2.1) 
   Doing unpaid or voluntary work 1,568 (0.5) 278 (0.5) 591 (0.4) 642 (0.5) 15 (0.4) 22 (0.4) 20 (0.5) 
   Full or part-time student 929 (0.2) 183 (0.3) 336 (0.3) 382 (0.2) 10 (0.2) 11 (0.2) 7 (0.1) 
Ethnicity, n (%)        
   White 328,088 (94.5) 55,634 (91.2) 130,014 (95.2) 130,896 (96.2) 2,955 (78.8) 4,719 (87.9) 3,870 (90.9) 
   South Asian 6,601 (1.9) 2,602 (4.3) 2,245 (1.6) 870 (0.6) 478 (12.8) 309 (5.8) 98 (2.3) 
   Black 5,930 (1.7) 1,084 (1.8) 1,938 (1.4) 2,355 (1.7) 160 (4.3) 194 (3.6) 199 (4.7) 
   Chinese 1,221 (0.4) 373 (0.6) 512 (0.4) 275 (0.2) 24 (0.6) 25 (0.5) 12 (0.3) 
Mixed background / others 5,290 (1.5) 1,287 (2.1) 1,970 (1.4) 1,703 (1.3) 132 (3.5) 120 (2.2) 78 (1.8) 
Smoking status, n (%)          
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   Never 198,235 (57.1) 36,187 (59.3) 79,118 (57.9) 76,381 (56.1) 1,942 (51.8) 2,659 (49.5) 1,948 (45.8) 
   Previous 115,472 (33.3) 18,597 (30.5) 44,707 (32.7) 46,654 (34.3) 1,429 (38.1) 2,205 (41.1) 1,880 (44.2) 
   Current 33,423 (9.6) 6,195 (10.2) 12,854 (9.4) 13,064 (9.6) 378 (10.1) 503 (9.4) 429 (10.0) 
Obesity-related markers        
BMI, mean (SD) 27.2 (4.6) 27.1 (4.7) 26.8 (4.4) 27.1 (4.4) 31.1 (6.0) 31.0 (5.7) 31.2 (5.6) 
BMI Categories, n (%)        
   Underweight  (<18.5) 1,659 (0.5) 448 (0.7) 754 (0.5) 439 (0.3) 11 (0.3) 4 (0.1) 3 (0.1) 
   Normal weight (18.5-24.9) 118,469 (34.1) 21,219 (34.8) 49,991 (36.6) 45,661 (33.6) 485 (12.9) 653 (12.2) 460 (10.8) 
   Overweight (25.0 to 29.9) 148,864 (42.9) 25,418 (41.7) 58,380 (42.7) 60,315 (44.3) 1,319 (35.2) 1,912 (35.6) 1,520 (35.7) 
   Obese (≥30.0) 78,138 (22.5) 13,894 (22.8) 27,554 (20.2) 29,684 (21.8) 1,934 (51.6) 2,798 (52.1) 2,274 (53.4) 
Waist Circumference (cm), mean (SD) 89.6 (13.1) 89.6 (13.1) 88.6 (12.8) 89.3 (12.8) 102.5 (14.5) 101.8 (14.2) 101.6 (14.1) 
Central Obesity, n (%) 108,502 (31.3) 19,575 (32.1) 39,323 (28.8) 41,112 (30.2) 2,401 (64.1) 3,355 (62.5) 2,736 (64.3) 
% Body fat, mean (SD) 31.0 (8.5) 31.5 (8.6) 30.9 (8.4) 30.6 (8.4) 33.8 (8.6) 33.4 (8.5) 33.4 (8.6) 
Fitness, Physical activity and Sleep, mean 
(SD) 
       
Grip strength (kg) 31.2 (11.0) 21.3 (7.6) 29.2 (8.3) 37.7 (10.5) 22.0 (7.4) 30.9 (8.0) 38.9 (10.1) 
Total physical activity (MET.h.week-1) 6.6 (9.1) 5.9 (8.8) 6.5 (9.0) 7.0 (9.3) 4.9 (8.4) 5.6 (8.0) 6.2 (8.9) 
TV-viewing (h.day-1) 2.7 (1.6) 2.8 (1.7) 2.7 (1.5) 2.6 (1.5) 3.5 (2.0) 3.3 (1.8) 3.2 (1.7) 
PC-screen time (h.day-1) 1.2 (1.3) 1.2 (1.4) 1.2 (1.3) 1.2 81.3) 1.3 (1.6) 1.3 (1.6) 1.3 (1.4) 
Sleep Time categories n (%)        
Normal 7-9 h 259,008 (74.9) 43,542 (71.8) 102,490 (75.2) 103,643 (76.3) 2,480 (66.7) 3,786 (70.9) 3,067 (72.3) 
Short sleepers <7 h 82,776 (23.9) 16,059 (26.5) 32,219 (23.7) 30,901 (22.8) 1,108 (29.8) 1,410 (26.4) 1,079 (25.5) 
Long sleepers >9 h 4,190 (1.2) 1,035 (1.7) 1,542 (1.1) 1,239 (0.9) 132 (3.5) 148 (2.7) 94 (2.2) 
Dietary intakes, mean (SD)        
Total energy (Kcal.day-1) 2,118 (645) 2,097 (666) 2,109 (636) 2,136 (641) 2,080 (731) 2,093 (684) 2,128 (686) 
Protein intake (% of TE) 15.5 (3.6) 15.5 (3.7) 15.5 (3.6) 15.6 (3.6) 16.2 (4.2) 16.2 (4.0) 16.4 (3.7) 
Carbohydrate intake (% of TE) 47.2 (8.1) 47.7 (8.4) 47.2 (8.1) 46.9 (8.0) 47.0 (8.8) 46.4 (8.3) 45.9 (8.3) 
Total fat intake (% of TE) 32.0 (6.7) 31.9 (6.8) 32.0 (6.7) 32.1 (6.6) 32.7 (7.2) 32.4 (7.0) 32.8 (7.0) 
Saturated intake (% of TE) 12.3 (3.3) 12.2 (3.4) 12.2 (3.3) 12.3 (3.3) 12.4 (3.6) 12.4 (3.5) 12.4 (3.4) 
Sugar intake (% of TE) 22.5 (7.0) 22.7 (7.3) 22.5 (6.9) 22.5 (6.8) 20.4 (7.4) 20.2 (6.8) 20.0 (6.7) 
Alcohol intake (% of TE) 5.3 (6.5) 4.9 (6.5) 5.3 (6.5) 5.4 (6.4) 4.1 (6.7) 4.9 (7.1) 4.9 (6.9) 
Red meat intake (portion.week-1) 1.9 (1.4) 1.9 (1.4) 1.9 (1.4) 1.9 (1.4) 2.1 (1.7) 2.1 (1.6) 2.1 (1.5) 
Processed meat intake (portion.week-1) 1.9 (1.1) 1.9 (1.1) 1.9 (1.1) 1.9 (1.0) 2.0 (1.1) 2.0 (1.1) 2.0 (1.0) 
Vegetable and Fruit intake (grams.day-1)  330.4 (192.0) 322.9 (201.9) 327.3 (189.0) 334.5 (188.5) 346.8 (201.0) 352.3 (204.5) 361.8 (214.8) 
Oily fish (portion.week-1) 1.1 (1.0) 1.1 (1.0) 1.1 (1.0) 1.1 (1.0) 1.1 (1.2) 1.2 (1.1) 1.2 (1.1) 
Health status        
Number of years with diabetes, mean(SD) 0.2 (1.6) 0 0 0 6.7 (6.4) 6.0 (5.8) 5.5 (5.7) 
Systolic blood pressure (mmHg), mean (SD) 139.7 (19.6) 138,1 (19.6) 139.2 (19.7) 140.5 (19.5) 142.8 (18.6) 144.3 (18.1) 145.3 (17.9) 
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Diastolic blood pressure (mmHg), mean (SD) 82.5 (10.7) 81.7 (10.8) 82.2 (10.7) 83.0 (10.6) 81.6 (10.0) 82.5 (9.9) 83.4 (10.0) 
High blood pressure history, n (%) 79,937 (23.0) 14,243 (23.4) 29,264 (21.4) 28,573 (21.0) 2,224 (59.3) 3,178 (59.2) 2,455 (57.7) 
Medication for cholesterol or blood pressure, n 
(%) 
       
   None of the above 310,655 (89.5) 54,200 (88.9) 123,477 (90.3) 123,690 (90.9) 2,614 (69.7) 3,761 (70.1) 2,913 (68.4) 
   Cholesterol lowering medication 18,119 (5.2) 3,184 (5.2) 5,977 (4.4) 5,461 (4.0) 963 (25.7) 1,393 (26.0) 1,141 (26.8) 
   Insulin 117 (0.04) 0 0 0 51 (1.2) 39 (0.7) 27 (0.7) 
   Blood pressure medication 18,356 (5.3) 3,595 (5.9) 7,225 (5.3) 6,948 (5.1) 172 (4.6) 213 (3.9) 203 (4.8) 
Data presented as mean and SD for continuous variables or n and % for categorical variables. F&V: fruit and vegetable, CVD:  cardiovascular diseases, n: numbers, SD: 
standard deviation, TE: total energy. *Data was available for n=210,064 participants.  
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Table 2. Cox proportional hazard ratio for all-cause mortality and CVD incidence and mortality in people with diabetes 
 Total n Deaths / events HR (95% CI) P-value 
All-cause mortality     
Model 0 347,130 6,209 1.72 (1.58; 1.88) <0.0001 
Model 1 347,130 6,209 1.65 (1.51; 1.81) <0.0001 
Model 2 347,130 6,209 1.55 (1.42; 1.70) <0.0001 
CVD mortality     
Model 0 347,130 594 2.19 (1.71; 2.80) <0.0001 
Model 1 347,130 594 2.07 (1.61; 2.67) <0.0001 
Model 2 347,130 594 1.95 (1.50; 2.52) <0.0001 
CVD incidence      
Model 0 347,130 4,301 1.44 (1.29; 1.61) <0.0001 
Model 1 347,130 4,301 1.36 (1.21; 1.52) <0.0001 
Model 2 347,130 4,301 1.22 (1.09; 1.37) 0.001 
Circulatory 
mortality 
    
Model 0 347,130 1,811 2.49 (2.17; 2.85) <0.0001 
Model 1 347,130 1,811 2.22 (1.93; 2.55) <0.0001 
Model 2 347,130 1,811 2.00 (1.74; 2.31) <0.0001 
Circulatory 
incidence  
    
Model 0 347,130 19,130 1.50 (1.42; 1.58) <0.0001 
Model 1 347,130 19,130 1.34 (1.27; 1.42) <0.0001 
Model 2 347,130 19,130 1.22 (1.16; 1.29) <0.0001 
Data presented as hazard ratio and 95% CI. People without diabetes were used as reference category. Participants who were diagnosed with diabetes before the age of 30 years 
were removed from the analysis. All-analysis were performed as a landmark analysis with follow-up commenced two years after recruitment and including participants who 
were event-free at this time. In addition, participants with comorbidities at baseline were excluded from all-analysis (depression, COPD, chronic asthma, chronic liver diseases, 
alcohol problems, substance abuse, eating disorders, schizophrenia, cognitive impartment, Parkinson, dementia, chronic pain syndrome, heart diseases, inflammatory diseases, 
arthrosis, arthritis and cancer (n= 103,755). 
Model 0 was adjusted for age, sex, ethnicity, deprivation index, professional qualifications, gross income, employment and month of recruitment.   
Model 1 was also adjusted for duration of diabetes, systolic blood pressure, and baseline prevalence of hypertension and history of recent medication for diabetes (insulin), 
hypertension and cholesterol.  
Model 2 was also adjusted for BMI categories, smoking, TV-viewing, PC-screen time, categories of sleep duration and dietary intake (alcohol, fruit and vegetable, red meat, 
processed meat and oily fish intake). 
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Table 3. Cox proportional hazard ratio for all-cause mortality and CVD incidence and mortality in people with diabetes by grip strength categories. 
    Categories of age and sex specific grip strength    
All-cause 
mortality 
 Total n Deaths/ 
events 
Higher Middle Lower 
HR-trend  
(95% CI) 
P-trend 
P-interaction 
Model 0 Without diabetes 
333,757 5,640 
1.00 
(Ref.) 
1.22 (1.15; 1.29) 1.69 (1.57; 1.81) 
1.29 (1.25; 
1.34) 
<0.0001 
 With diabetes 
13,373 569 
1.00 
(Ref.) 
1.29 (1.05; 1.59) 2.04 (1.65; 2.53) 
1.44 (1.29; 
1.60) 
<0.0001 
Model 1 Without diabetes 
333,757 5,640 
1.00 
(Ref.) 
1.23 (1.16; 1.30) 1.70 (1.59; 1.83) 
1.30 (1.25; 
1.34) 
<0.0001 
 With diabetes 
13,373 569 
1.00 
(Ref.) 
1.32 (1.07; 1.62) 2.10 (1.70; 2.61) 
1.46 (1.31; 
1.63) 
<0.0001 
Model 2 Without diabetes 
333,757 5,640 
1.00 
(Ref.) 
1.23 (1.16; 1.30) 1.70 (1.58; 1.82) 
1.30 (1.25; 
1.34) 
<0.0001 
 With diabetes 
13,373 569 
1.00 
(Ref.) 
1.34 (1.09; 1.66) 2.05 (1.65; 2.54) 
1.44 (1.29; 
1.60) 
<0.0001 
CVD 
mortality 
 
     
  
 
Model 0 Without diabetes 
333,757 519 
1.00 
(Ref.) 
1.27 (1.04; 1.55) 1.71 (1.36; 2.16) 
1.30 (1.16; 
1.47) 
<0.0001 
 With diabetes 
13,373 75 
1.00 
(Ref.) 
1.52 (0.82; 2.81) 2.62 (1.42; 4.81) 
1.63 (1.20; 
2.21) 
0.002 
Model 1 Without diabetes 
333,757 519 
1.00 
(Ref.) 
1.30 (1.07; 1.58) 1.78 (1.41; 2.25) 
1.33 (1.18; 
1.49) 
<0.0001 
 With diabetes 
13,373 75 
1.00 
(Ref.) 
1.61 (0.87; 2.99) 2.83 (1.53; 5.21) 
1.69 (1.25; 
2.29) 
0.001 
Model 2 Without diabetes 
333,757 519 
1.00 
(Ref.) 
1.30 (1.07; 1.59) 1.78 (1.40; 2.25) 
1.33 (1.18; 
1.49) 
<0.0001 
 With diabetes 
13,373 75 
1.00 
(Ref.) 
1.69 (0.91; 3.13) 2.88 (1.55; 5.35) 
1.70 (1.25; 
2.30) 
0.001 
CVD 
incidence  
 
     
  
 
Model 0 Without diabetes 
333,757 3,966 
1.00 
(Ref.) 
1.20 (1.12; 1.29) 1.45 (1.33; 1.58) 
1.20 (1.15; 
1.26) 
<0.0001 
 With diabetes 
13,373 335 
1.00 
(Ref.) 
1.08 (0.82; 1.42) 1.87 (1.43; 2.46) 
1.39 (1.20; 
1.60) 
<0.0001 
Model 1 Without diabetes 333,757 3,966 1.00 1.23 (1.15; 1.32) 1.51 (1.39; 1.65) 1.23 (1.18; <0.0001 
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(Ref.) 1.28) 
 With diabetes 
13,373 335 
1.00 
(Ref.) 
1.12 (0.85; 1.47) 1.98 (1.50; 2.59) 
1.42 (1.24; 
1.64) 
<0.0001 
Model 2 Without diabetes 
333,757 3,966 
1.00 
(Ref.) 
1.23 (1.14; 1.32) 1.49 (1.36; 1.62) 
1.22 (1.17; 
1.27) 
<0.0001 
 With diabetes 
13,373 335 
1.00 
(Ref.) 
1.14 (0.87; 1.50) 1.98 (1.50; 2.60) 
1.42 (1.23; 
1.64) 
<0.0001 
Data is presented as hazard ratio and 95% CI. People on the highest category for grip strength were used as reference category. Participants who were diagnosed with diabetes 
before the age of 30 years were removed from the analysis. All-analysis were performed as a landmark analysis with follow-up commenced two years after recruitment and 
including participants who were event-free at this time. In addition, participants with comorbidities at baseline were excluded from all-analysis (depression, COPD, chronic 
asthma, chronic liver diseases, alcohol problems, substance abuse, eating disorders, schizophrenia, cognitive impartment, Parkinson, dementia, chronic pain syndrome, heart 
diseases, inflammatory diseases, arthrosis, arthritis and cancer (n= 103,755). 
Model 0 was adjusted for age, sex, ethnicity, deprivation index, professional qualifications, gross income, employment and month of recruitment.   
Model 1 was also adjusted for duration of diabetes, systolic blood pressure, and baseline prevalence of hypertension and history of recent medication for diabetes (insulin), 
hypertension and cholesterol.  
Model 2 was also adjusted for BMI categories, smoking, TV-viewing, PC-screen time, categories of sleep duration, physical activity and dietary intake (alcohol, fruit and 
vegetable, red meat, processed meat and oily fish intake). 

SUPPLEMENTARY MATERIAL 
Table S1. Cut-off points for age and sex specific grip strength categories. 
Sex Age group T1 (Lower) T2 T3 (Higher) 
Women <56 years <23 23 – 28 >28 
 56 to 65 years <20 20 – 25 >25 
 >65 years <18 18 – 23 >23 
Men <56 years <38 38 – 46 >46 
 56 to 65 years <35 35 – 42 >42 
 >65 years <33 33 – 39 >39 
Data presented as kg. 
